Skip to main content

← Back to results

HEALTH AND HUMAN SERVICES, DEPARTMENT OF › NATIONAL INSTITUTES OF HEALTH › NATIONAL INSTITUTES OF HEALTH NIAID

AUTOIMMUNE DISEASES STATISTICAL & CLINICAL COORDINATING CENTER (AD-SCCC)

Key facts

Response deadline
Dec 1, 2026
3:00 PM UTC-05:00
Set-aside
No set-aside
No Set aside used
Notice type
Presolicitation (originally Sources sought)
Posted on SAM.gov
Nov 16, 2026
Archives Dec 16, 2026

Description

Anticipated Period of Performance The anticipated period of performance is February 1, 2027 through January 31, 2028, with an option to extend services for an additional 6 month period, through July 31, 2028. Anticipated award date: February 1, 2027 The NAICS Code is 541715. Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Allergy, Immunology, and Transplantation (DAIT) has a requirement to support a broad range of services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. The major clinical research programs to be supported by this solicitation include, Autoimmunity Centers of Excellence and Immune Tolerance Network (ACE), as well as investigator initiated clinical trials (IICT), and other clinical trials or study activities supported by NIAID herein collectively referred to as NIAID supported research. Description Topic Title:
Show more
Autoimmune Diseases Statistical & Clinical Coordinating Center (ADSCCC) The Division of Allergy, Immunology, and Transplantation (DAIT), National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), project is for work related to the contract below: “Autoimmune Diseases Statistical & Clinical Coordinating Center (AD-SCCC)”, RHO Federal Systems Division, Inc. (Contract 75N93022C00003) This contract was awarded on a competitive basis for a five-year period from February 1, 2022 through January 31, 2027. A term type/level of effort contract was awarded for the delivery of 56,170 direct labor hours per year for Years 1-5. The total value of the contract is $49,268,667 and includes options for extension of the term for a total performance period of 5 years and options for increases in the level of effort, with the purpose of establishing an Autoimmune Diseases Statistical & Clinical Coordinating Center (AD- SCCC) that will provide a broad range of support critical for the design, development, execution, and analysis of clinical research sponsored by NIAID in autoimmune diseases and diseases related to mucosal immunology and primary immune deficiencies. The scope of clinical research to be supported by the AD- SCCC includes: (i) clinical trials at all phases to evaluate the safety and efficacy of investigational products and innovative approaches for disease treatment and prevention; (ii) studies of underlying mechanisms as integral components of clinical trials; (iii) clinical studies (e.g., genetic studies, microbiome studies, surveys of current therapies, etc.); and (iv) surrogate/biomarker studies. The scope of statistical and clinical support functions to be performed by the AD-SCCC includes statistical design and analysis; protocol development; study initiation and management; clinical safety and pharmacovigilance support; safety oversight; management of clinical study collaboration portals; manuscript preparation and management of sample repositories. The NIAID, NIH, conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. The causes, pathogenesis, diagnosis, treatment, and prevention of autoimmune diseases are major areas of emphasis for NIAID’s Division of Allergy, Immunology, and Transplantation (DAIT). DAIT pursues research on autoimmune diseases by supporting investigator-initiated research projects, cooperative clinical studies, national networks of research centers, and demonstration and education research projects. A critical component of the Division’s mission focuses on clinical research to develop new and/or improved strategies to treat or prevent autoimmune diseases through rigorous evaluations of the safety and efficacy of investigational products and therapeutic interventions, studies to elucidate underlying mechanisms of disease, studies to develop and evaluate surrogate/biomarkers of disease stage, severity and progression, and clinical studies of disease natural history. The purpose of this acquisition is to extend the period of performance of the current contract (through July 31, 2028), beginning February 1, 2027, thereby maintaining the same direct labor hours to maintain ongoing clinical trial operations while DAIT completes the competition under the Clinical Data, Safety, and Coordinating Centers (CDSCC) NOFO. The extension retains the existing scope and contract type. The required research and development clinical trial activities are severable in nature, the 18-month extension will be structured as two discrete option periods. Specifically, the Contractor will be responsible for the following: A. Statistical Design Provide expertise, advice and assistance pin the development of statistical design plans for the development of concept and full study proposals for NIAID supported clinical research; Provide assistance in the preparation of concept and full proposals and study-specific protocols; Provide assistance in the preparation of concept and full proposals and protocols for mechanistic studies; Provide support for preclinical safety study evaluation by providing statistical expertise for, and participate in, evaluating the accuracy and validity of data from preclinical safety studies in support of clinical trials if applicable; Provide assistance for clinical trials and mechanistic studies post-study initiation. B. Statistical Analysis Development and preparation of the Statistical Analysis Plan (SAP) for each clinical trial in conjunction with the Study Management Teams (SMTs); Preparation of interim and final analyses; Preparation of summary data reports; Development and preparation of results for posting as required by ClinicalTrials.gov; Review of the accuracy and completeness of statistical data and data analyses for all abstracts, manuscripts, and presentations reporting on the clinical studies conducted by the relevant NIAID-sponsored networks and investigators prior to presentation or submission for publication. Collaboration with NIAID-supported research, including the NIAID Clinical Data and Safety Management Center (CDSMC); C. Protocol Development and Study Initiation Provide expert advice and assistance to SMTs in the development of protocols for clinical trials and mechanistic studies; Provide expert advice, assistance and coordination in the preparation, writing, review and approval of protocol-related documents and materials in collaboration with NIAID, SMTs, and the CDSMC and other NIAID supported research. D. Data Management and Reporting E. Clinical Safety and Pharmacovigilance Center Support F. Safety Oversight Structure Support G. Clinical Study Internet-Based Collaboration Portals H. Training I. Repository of Biological Specimens J. Other Technical and Administrative Support K. Scientific and Technical Personnel L. Facilities, Equipment and Other Resources M. Quality Assurance/Quality Control N. Overall Project Management O. Initial and Final Transitions The NIAID intends to negotiate, under the authority of RFO - FAR Part 6.302-1 and HHSAR Part 306.302-1, on a sole source basis with Rho, to modify the existing contract to extend the current contract by a total of 18-months [Term Option 5 (12-months, February 1, 2027 through January 31, 2028), and Term Option 6 (6-months, February 1, 2028 through July 31, 2028)]. Due to the complex nature of DAIT clinical trial operations and the need for a contractor to perform the required AD-SCCC services during the interim period, the requirement is to maintain support for the existing portfolio without an interruption in protocol operations, statistical support, data coordination, or safety oversight beginning February 1, 2027. Rho’s demonstrated personnel qualifications, staffing, relevant experience, and current protocol-specific knowledge support its ability to meet that requirement. Attempting to bring in a new contractor would result in a significant disruption to critical services and could jeopardize participant safety and data integrity. Using the current contractor for the extension of services allows for continuity of operations in this highly regulated environment and helps to ensure we are able to maintain during this interim period the services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. This notice of intent is not a request for competitive proposals. However, responsible sources may express their interest by submitting a capability statement. All capability statements received within fifteen days from the date of the publication of this notice will be considered by the Government. A determination by the Government not to compete this proposed contract action based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. This proposed acquisition was previously published under a Research and Development Sources Sought Notice that was posted on the System for Award Management (SAM.gov) website on February 20, 2026 as notice number HHS–NIH–NIAID–RDSS–26–75N93026R00009.

From SAM.gov’s daily data file, as published on Nov 17, 2026 (UTC).

Contacts

Attachments

BidLookup records the links this notice gives. It has not downloaded or checked the files.

Record dates

Posted on SAM.gov: Nov 16, 2026
The agency’s publication date, as SAM.gov states it.
First recorded by BidLookup: Nov 16, 2026
The UTC day of the first read of SAM.gov’s listings that stored this notice.
Last confirmed: Nov 17, 2026
The UTC day of the latest read that still listed this notice. It does not mean the notice is unchanged or still open on SAM.gov now, and it is not the index’s last-read time.
Description as published: Nov 17, 2026 (UTC)
The date of the daily data file this text came from.

Published by the agency on SAM.gov as notice 002dc02c4a8647aca6d0a1c2a5d07535. What these dates mean

Record

Solicitation number
75N93026R00009
Search the index for this number
NAICS
541715 · Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Product/service code
AN12 · HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Place of performance
Durham, North Carolina 27713
Contracting office
BETHESDA, MD 20892
SAM.gov notice ID
002dc02c4a8647aca6d0a1c2a5d07535